eligibility_summary
Adults (>=18) with measurable DLBCL, FL3b, or PMBCL (incl. transformed FL/MZL), asymptomatic secondary CNS allowed. Must be eligible for FDA-approved CD19 CAR-T, LD <=60d after reg, infusion 2-14d post-LD. Bridging allowed except polatuzumab/mosunetuzumab. PS 0-2, EF >=40%, CrCl >=40, AST/ALT <=3xULN, bili <=2xULN, neuropathy <grade 2, controlled HBV/HCV/HIV. Step 2: day 25-40 PET-CT SD/PR, randomize <=60d post-CAR-T. Step 3: progression on observation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Randomized phase II evaluating consolidation after commercial CD19 CAR T cells (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel) in R/R DLBCL or FL3B. Consolidation arms: mosunetuzumab (IV bispecific monoclonal antibody, CD20×CD3 T‑cell engager that activates endogenous T cells via CD3 to kill CD20+ B cells), polatuzumab vedotin (IV anti‑CD79b antibody–drug conjugate delivering MMAE, a microtubule inhibitor, to CD79b+ B cells), or both, versus observation. All receive prior lymphodepletion with fludarabine (purine analog) and cyclophosphamide (alkylator). Targets/pathways: malignant B cells expressing CD19 (CAR T), CD20 (mosunetuzumab), CD79b/BCR complex (polatuzumab), T‑cell activation via CD3/CAR, microtubule disruption by MMAE.